MarketCap
Facebook
X
TelegramObalon Therapeutics, Inc. Net Income | OBLN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Obalon Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -12.3 M | -23.7 M | -37.4 M | -34.8 M | -20.5 M | -15.6 M | -9.89 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.89 M | -37.4 M | -22 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 9.7 | -1.12 % | $ 384 M |  Curacao |
 |
TransMedics Group
TMDX
|
190 M | $ 71.03 | 0.41 % | $ 2.41 B |  USA |
 |
Aethlon Medical
AEMD
|
-7.15 M | $ 5.05 | 1.78 % | $ 3.4 M | USA |
 |
AxoGen
AXGN
|
-15.7 M | $ 38.31 | 0.64 % | $ 1.76 B | USA |
 |
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
-47 M | - | - | $ 726 K | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
-22 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-55.7 M | - | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
-54.6 M | - | -32.98 % | $ 1.68 M | USA |
 |
Butterfly Network
BFLY
|
-77.1 M | $ 6.78 | 0.37 % | $ 1.68 B | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
147 M | - | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
-1.64 M | - | - | $ 4.23 B | USA |
 |
Abiomed
ABMD
|
137 M | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Titan Medical
TMDI
|
-14.9 M | - | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
ThermoGenesis Holdings
THMO
|
-18.9 M | - | -25.84 % | $ 171 K | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
-62 M | - | 3.55 % | $ 7.96 M | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Viveve Medical
VIVE
|
-22 M | - | -15.35 % | $ 1.71 M | USA |
 |
SmileDirectClub
SDC
|
-86.4 M | - | -53.45 % | $ 9.71 M | USA |
 |
ViewRay
VRAY
|
-107 M | - | 1.54 % | $ 468 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 47.96 | -2.48 % | $ 1.49 B | USA |
 |
Acutus Medical
AFIB
|
-9.55 M | - | -26.83 % | $ 2.62 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 9.05 | -1.04 % | $ 256 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Vapotherm
VAPO
|
-58.2 M | - | 6.72 % | $ 34 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 14.66 | 1.66 % | $ 525 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
-54.3 M | - | 0.28 % | $ 270 M | USA |
 |
Zynex
ZYXI
|
2.99 M | - | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Medigus Ltd.
MDGS
|
4.05 M | - | 10.28 % | $ 55.5 M |  Israel |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 81.12 | -0.36 % | $ 11 B | USA |
 |
Nemaura Medical
NMRD
|
-14.1 M | - | -17.8 % | $ 2.74 M |  Britain |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | Canada |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-517 M | $ 12.07 | 1.34 % | $ 925 M | USA |
 |
InMode Ltd.
INMD
|
93.8 M | $ 13.77 | -1.43 % | $ 890 M | Israel |
 |
Apyx Medical Corporation
APYX
|
-11.2 M | $ 2.41 | 1.69 % | $ 99 M | USA |
 |
Accuray Incorporated
ARAY
|
-49.2 M | $ 0.12 | -4.69 % | $ 14.7 M | USA |
 |
IRadimed Corporation
IRMD
|
22.5 M | $ 85.76 | -0.12 % | $ 1.09 B | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 126.54 | -0.01 % | $ 4.4 B | USA |
 |
Inogen
INGN
|
22.7 M | $ 7.05 | -0.77 % | $ 188 M | USA |
 |
Bruker Corporation
BRKR
|
-8.3 M | $ 57.98 | 0.68 % | $ 8.8 B | USA |